Prof. Adrian Newland (who is not related to ANGLE’s Chief Executive) is Professor of Haematology at Barts Health NHS Trust and Queen Mary University of London.
Prof. Newland was also Director of Pathology for the Trust and Clinical Director of the North East London Cancer Network until 2018. Prof. Newland was President of the Royal College of Pathologists from 2005 to 2008 and the International Society of Hematology from 2014 to 2016. Prof. Newland chaired the National Blood Transfusion Committee and was pathology lead for NHS London. Prof. Newland was National Clinical Advisor in Pathology to NHS Improvement and Clinical Advisor to the Transforming Cancer Service Team in London. He chaired the National Pathology Implementation Optimisation Delivery Group until 2020.
Prof. Newland was previously chair of the Diagnostic Assessment Programme for the National Institute for Health and Clinical Excellence (NICE) and of the NICE Sifting Group for cancer drugs. Prof. Newland has been a member of the Scientific Advisory Panel of the Institute of Cancer Research from 1995 until 2003 and Chair of the London Cancer New Drugs Group since 2002. Prof. Newland was a member of the National Chemotherapy Implementation Group until 2018 and a member of the Expert Reference Group on Cancer Care in London, the National Cancer Outcomes Advisory Group and the Human Genome Strategy Group. Prof. Newland is co-chair of the WHO Strategic Advisory Group of Experts for In-Vitro Diagnostic Devices (SAGE-IVD) and recently completed the five-year review of the WHO Cancer programme. He is currently a non-executive director of the UK Accreditation Service and chairs their Healthcare Forum.LinkedIn